Caris Life Sciences, Inc. (Nasdaq: CAI) delivered a landmark first quarter in 2026. The Texas-based precision medicine company posted $216.2 million in total revenue — a remarkable 79% jump over the same period last year. Moreover, the company swung from a $102.6 million net loss in Q1 2025 to near-breakeven, reporting a net loss of just $0.5 million. These results signal a powerful inflection point for one of healthcare’s most ambitious AI-driven platforms.
Revenue Soars on Molecular Profiling Strength
Molecular profiling services form the backbone of Caris’ business model, and Q1 2026 proved that foundation is rock solid. The segment generated $210.8 million in revenue, up 85% from $114.1 million in the prior year quarter. Two key drivers fueled this growth: higher clinical case volumes and improved average selling prices (ASP) across therapy selection solutions.
Furthermore, gross profit climbed sharply to $141.3 million, up from $57.1 million in Q1 2025. Consequently, gross margin expanded dramatically — from 47% to 65% — an improvement of approximately 1,800 basis points. This level of margin expansion reflects both scale benefits and pricing discipline.
Operating expenses rose to $136.1 million, a more controlled 18% increase driven by stock-based compensation and headcount investments. As a result, Caris reported a positive Adjusted EBITDA of $26.2 million, compared to a negative $36.2 million in Q1 2025 — a reversal that underscores accelerating operational leverage.
Clinical Case Volume Reaches New Heights
Record February and March Performance
Caris completed approximately 52,800 clinical therapy selection cases during the quarter — a 15% increase over Q1 2025. The mix included roughly 43,600 MI Profile cases and 9,200 Caris Assure cases. Notably, the company re-aligned its sales force in January 2026. Despite that disruption, February and March delivered record volume, exiting at a quarterly run-rate of approximately 56,000 completed cases.
“We delivered another strong quarter with record performance for February and March following our January sales re-alignment,” said David Dean Halbert, Founder, Chairman, and CEO. “This performance underscores the continued demand for our platform and the strength of our comprehensive, patient-first approach.”
Additionally, Caris surpassed 1,070,000 total profiles and 790,000 total matched profiles through March 31, 2026. This milestone includes more than 677,000 whole exome profiles and 728,000 whole transcriptome profiles — one of the largest clinico-genomic databases in the world.
Key Product Launches Drive Innovation
Caris ChromoSeq: Myeloid Cancer Profiling
Caris launched Caris ChromoSeq, a comprehensive whole genome tumor profiling assay targeting myeloid malignancies, and received MolDX approval. This approval opens access to broader reimbursement and accelerates clinical adoption.
Caris MI Clarity: AI-Powered Breast Cancer Tool
The company also launched Caris MI Clarity, a next-generation prognostic tool that uses multimodal AI and computational pathology. It delivers rapid, clinically actionable results for HR+/HER2−, postmenopausal, node-negative early-stage breast cancer patients. Specifically, it predicts both early and late distant recurrence risk at the time of diagnosis.
Caris AI Insights: Expanding Oncology Guidance
Powered by whole exome and whole transcriptome data, Caris added three new AI Insights modules. These tools guide first-line therapy selection in pancreatic cancer, identify early platinum resistance in ovarian cancer, and assess chemotherapy benefit for NSCLC patients.
Additionally, the Achieve 1 study results reinforced the superior sensitivity and specificity of Caris Detect. CEO Halbert noted the blinded readout demonstrates whole genome technology’s advantages over methylation-based techniques.
Q1 2026 Financial Results at a Glance
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total Revenue | $216.2M | $120.9M | +79% |
| Molecular Profiling Revenue | $210.8M | $114.1M | +85% |
| Gross Profit | $141.3M | $57.1M | +148% |
| Gross Margin | 65% | 47% | +1,800 bps |
| Net Loss | $(0.5M) | $(102.6M) | Improved 99.5% |
| Adjusted EBITDA | $26.2M | $(36.2M) | Positive swing |
Balance Sheet and Cash Flow Highlights
Strong Liquidity Position
Caris exited Q1 2026 with cash, equivalents, and restricted cash of $821.1 million. Total assets stood at $1.16 billion, while total shareholders’ equity reached $593.5 million. These figures reflect a healthy capital structure following the company’s IPO last year.
Positive Free Cash Flow Achieved
Net cash from operating activities reached $32.9 million — a 205% improvement from the $(31.3) million used in Q1 2025. After capital expenditures of $10.3 million, free cash flow came in at $22.5 million. Notably, this included $30.5 million in annual bonus payments, making the underlying cash performance even stronger.
In addition, Caris refinanced its $400 million credit facility at a lower borrowing cost. The company also secured access to additional strategic capital from Blue Owl and Blackstone, further strengthening its financial flexibility.
Full Year 2026 Guidance Reaffirmed
Caris reaffirms its full year 2026 revenue guidance of $1.0 billion to $1.02 billion. This represents growth of 23% to 26% compared to full year 2025. In parallel, the company targets approximately 20% growth in clinical therapy selection volume year-over-year.
Together, these milestones position Caris Life Sciences as one of the most compelling growth stories in healthcare technology today. With a diversified product pipeline, expanding molecular database, and strong cash generation, the company heads into the second half of 2026 with clear momentum.
